Advertisement

Virchows Archiv A

, Volume 372, Issue 1, pp 81–88 | Cite as

Morphological changes in the lymphoid organs induced by diphenylhydantoin sodium (DPH)

  • I. G. H. Lorand
  • W. A. Hadler
  • L. S. Prigenzi
Article
  • 15 Downloads

Summary

In rats injected with DPH the morphological changes induced in the thymus and lymph nodes were studied. In the thymus, features suggesting block of cellular differentiation were found, and in lymph nodes depletion of the paracortical zone and intense plasma cell hyperplasia could be observed. The correlation of these findings with the functional changes in the immunological response induced by the drug, and the possible implications of these changes in the induction of lymphoma are discussed.

Key words

Hydantoins Immunosuppression Lymphoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aisenberg, A.C.: Malignant lymphoma. New Engl. J. Med. 288, 883–890 (1973)Google Scholar
  2. Alarcon-Segovia, D., Fishbein, E., Reyes, P.A., Dies, H., Shawadsky, S.: Antinuclear antibodies in patients on anticonvulsant therapy. Clin. exp. Immunol. 12, 39–47 (1972)Google Scholar
  3. Anthony, J.J.: Malignant lymphoma associated with hydantoin drugs. Arch. Neurol. 22, 450–454 (1970)Google Scholar
  4. Beernink, D.H., Miller III, J.J.: Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children. J. Pediat. 82, 113–117 (1973)Google Scholar
  5. Bobrove, A.M., Fuks, Z., Strober, S., Kaplan, H.S.: Quantitation of T- and B lymphocytes and cellular immune function in Hodgkin's disease. Cancer (Philad.) 36, 169–179 (1975)Google Scholar
  6. Charlton, M.H., Lunsford, D.: Le sostanze di idantoina come possibili cause del linfoma maligno. Minerva med. 62, 2185 (1971)Google Scholar
  7. De Srulijez, L.K., Pavlovsky, A., Pedace, E.A.: Linfoadenopatias inducidas por drogas anticonvulsivantes, estudio experimental. Medicina (B. Aires) 23, 14–19 (1963)Google Scholar
  8. Dyminsky, J.W., Forbes, J., Gebhardt, B., Nakao, Y., Konda, S., Smith, R.T.: Relationship between structure and function of human and mouse thymus cell subpopulations. Progr. Immunol. II 3, 35–47 (1974)Google Scholar
  9. Gams, R.A., Neal, J.A., Conrad, F.G.: Hydantoin-induced pseudopseudolymphoma. Ann. intern. Med. 69, 557–568 (1968)Google Scholar
  10. Gomes, F.P.: O teste de Tukey. In: Curso de estatística experimental. Piracicaba: Livraria Nobel de Piracicaba (1973)Google Scholar
  11. Gomori, G.: Silver impregnation of reticulum in paraffin sections. Amer. J. Path. 13, 993–994 (1937)Google Scholar
  12. Grob, P.J., Herold, G.E.: Immunological abnormalities and hydantoins. Brit. med. J. 2, 561–563 (1972)Google Scholar
  13. Hadler, W.A.: Morfologia e distribuição das células reticulates do baço normal. Estudo efetuado mediante técnica de impregnação argêntica. Tese de docência-livre. Departamento de Morfologia Humana. Faculdade de Medicina, Ribeirão Preto S.P. (1962), p. 8.Google Scholar
  14. Holland, P., Mauer, A.M.: Diphenylhydantoin-induced hypersensitivity-reaction. J. Pediat. 66, 322–332 (1965)Google Scholar
  15. Hyman, G.A., Sommers, S.C.: The development of Hodgkin's disease and lymphoma during anticon-vulsant therapy. Blood 28, 416–427 (1966)Google Scholar
  16. Hwang, W.S., Ho, T.Y., Luk, S.C., Simon, G.T.: Ultrastructure of the rat thymus. A transmission, scanning electron microscope, and morphometric study. Lab. Invest. 31, 473–487 (1974)Google Scholar
  17. Iashima, C.K.: Lymphoma and anticonvulsive therapy. J. Amer. med. Ass. 228, 286–287 (1974)Google Scholar
  18. Kaslaris, E.: Experimentelle Erzeugung von Lymphknotenschwellung durch Mesantoin. Wien. klin. Wschr. 65, 1007–1008 (1953)Google Scholar
  19. Krüger, G.: Effect of dilantin in mice: I. Changes in the lymphoreticular tissue after acute exposure. Virchows Arch. Abt. A Path. Anat. 349, 297–311 (1970)Google Scholar
  20. Krüger, G., Harris, D., Sussman, E.: Effect of dilantin in mice II.: Lymphoreticular tissue atypia and neoplasia after chronic exposure. Z. Krebsforsch. 78, 290–302 (1972)Google Scholar
  21. Lennert, K.: Lymphknotenveränderungen nach Hydantoin (Mesantoin) Medikation. In: Handbuch der speziellen pathologischen Anatomie und Histologie. Berlin-Heidelberg-New York: Springer 1961Google Scholar
  22. Levo, Y., Marckowitz, O., Trainin, N.: Hydantoin immunosupression and carcinogenesis. Clin. exp. Immunol. 19, 521–527 (1975)Google Scholar
  23. Li, F.P., Willard, D.R., Goodman, R., Vawter, G.: Malignant lymphoma after diphenylhydantoin (Dilantin) therapy. Cancer (Philad.) 36, 1359–1362 (1975)Google Scholar
  24. Lillie, R.D.: Methyl green-pironin. In: Histopathologic technic and practical histochemistry. New York: McGraw-Hill 1965Google Scholar
  25. Mitchell, G.F., Miller, J.F.A.P.: Cell to cell interaction in the immune response: II-The source of hemolysin forming cells in irradiated mice given bone marrow and thymus or thoracic duct lymphocytes. J. exp. Med. 128, 821–837 (1968)Google Scholar
  26. Morgenfeld, M.C., Somoza, N., Cavagnaro, F.: Linfadenitis por hidantoinatos. Sangre 15, 444–452 (1970)Google Scholar
  27. Müller-Hermelink, H.K.: Characterization of the B-cell and T-cell regions of human lymphatic tissue through enzyme histochemical demonstration of ATPase and 5′nucleotidase activities. Virchows Arch. B Cell Path. 16, 371–378 (1974)Google Scholar
  28. Palmer, A.A.: The diagnosis of lymphomas. Med. J. Aust. 2, 96–98 (1974)Google Scholar
  29. Parrott, D.M.V., Souza, M.A.B.: Thymus dependent and thymus independent populations: origin, migration patterns and life-span. Clin. exp. Immunol. 8, 663–684 (1971)Google Scholar
  30. Peckham, M.J.: Aetiologic leads in the malignant lymphomas. Clin. Hematol. 3, 3–37 (1974)Google Scholar
  31. Sainte-Marie, G., Leblond, C.P.: Tentative pattern for renewal of lymphocytes in cortex of the rat thymus. Proc. Soc. exp. Biol. (N.Y.) 97, 263–270 (1958)Google Scholar
  32. Saltzstein, S.L., Ackerman, L.V.: Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer. (Philad.) 12, 164–182 (1959)Google Scholar
  33. Seager, J., Jamison, D.L., Wilson, J., Hayward, A.R.: IgA deficiency, epilepsy and phenytoin treatment. Lancet 1975 II, 632–635Google Scholar
  34. Sorrel, T.C., Forbes, I.J., Burness, F.R., Rischbieth, R.H.C.: Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). Lancet 1971 II, 1233–1235Google Scholar
  35. Sorrel, T.C., Forbes, I.J.: Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro. Clin. exp. Immunol. 20, 273–285 (1975)Google Scholar
  36. White, A., Goldstein, A.L.: Thymosin, a thymic hormone influencing lymphoid cell immunological competence. In: Hormones and the immune response. Ciba Foundation Study Group 36. London: J.A. Churchill 1970Google Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • I. G. H. Lorand
    • 1
  • W. A. Hadler
    • 1
  • L. S. Prigenzi
    • 1
  1. 1.Department of Internal Medicine and Department of HistologyState University of CampinasCampinas, Estado de São PauloBrasil

Personalised recommendations